A preclinical study evaluating BCL-2 inhibitors and chemotherapy in breast cancer xenograft models demonstrated that BCL-2 targeted agents are more efficacious when used in combination with chemotherapy, which possibly explains the outcome of the VERONICA trial (59). The gene discussed is BCL2; the disease is breast carcinoma.